These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


709 related items for PubMed ID: 18617783

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.
    Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, Askari F, Sullivan P, Lok AS.
    Liver Transpl; 2007 Aug; 13(8):1100-8. PubMed ID: 17377914
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
    Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA.
    Transplant Proc; 2004 Aug; 36(6):1831-4. PubMed ID: 15350490
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C.
    Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, Rayón JM, Berenguer J.
    Liver Transpl; 2006 Jul; 12(7):1067-76. PubMed ID: 16622844
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
    Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
    [Abstract] [Full Text] [Related]

  • 12. Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.
    Merli M, Giannelli V, Gentili F, Giusto M, Simmaco M, Lionetto L, Corradini SG, Biliotti E, Attili AF, Rossi M, Taliani G.
    Antivir Ther; 2011 Aug; 16(6):879-85. PubMed ID: 21900720
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Outcomes of acute rejection after interferon therapy in liver transplant recipients.
    Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, Farmer DG, Ghobrial RM, Yersiz H, Goldstein LI, Lassman CR, Busuttil RW.
    Liver Transpl; 2004 Jul; 10(7):859-67. PubMed ID: 15237369
    [Abstract] [Full Text] [Related]

  • 15. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S, Hunt DR, Stone MA, McClune A, Tong MJ.
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation.
    Cescon M, Grazi GL, Cucchetti A, Vetrone G, Ravaioli M, Ercolani G, Morelli MC, Piscaglia F, Tamè M, Pinna AD.
    Liver Transpl; 2009 Jul; 15(7):782-9. PubMed ID: 19562715
    [Abstract] [Full Text] [Related]

  • 18. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
    Castells L, Vargas V, Allende H, Bilbao I, Luis Lázaro J, Margarit C, Esteban R, Guardia J.
    J Hepatol; 2005 Jul; 43(1):53-9. PubMed ID: 15876467
    [Abstract] [Full Text] [Related]

  • 19. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
    Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Reed A, Hemming A, Howard R, Van Der Werf W, Lauwers G, Liu C, Crawford JM, Davis GL, Nelson DR.
    Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712
    [Abstract] [Full Text] [Related]

  • 20. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
    Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, Saliba F, Duclos-Vallee JC, Castaing D, Samuel D.
    Liver Transpl; 2008 Dec; 14(12):1766-77. PubMed ID: 19025933
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 36.